Close Menu

NEW YORK – OraSure Technologies reported after the close of the market on Wednesday that its third quarter revenues increased 33 percent year over year driven by sales of its oral fluid collection devices for COVID-19 molecular tests.

For the three months ended Sept. 30, the point-of-care diagnostics company reported total revenues of $48.0 million, up from $36.0 million in the prior-year quarter. The Bethlehem, Pennsylvania-based company beat the consensus Wall Street estimate of $41.7 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.